Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Kempers

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
Dermatology and Therapy|May 11, 2023
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL StudyKalyani Marathe, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
The New England Journal of Medicine|February 10, 2021
Phase 3 Trials of Tirbanibulin Ointment for Actinic KeratosisAndrew Blauvelt, Steven Kempers, Edward Lain, et al.
Journal of the American Academy of Dermatology|July 25, 2022
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosisJoyce M C Teng, Christopher G Bunick, Scott Guenthner, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposureHolm Schneider, Christopher G Bunick, Kathrin Hillmann, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Journal of Drugs in Dermatology : JDD|August 4, 2010
Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimenDavid Pariser, Alicia Bucko, Richard Fried, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Science Advances|May 1, 2024
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
Dermatology and Therapy|May 11, 2023
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL StudyKalyani Marathe, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
The New England Journal of Medicine|February 10, 2021
Phase 3 Trials of Tirbanibulin Ointment for Actinic KeratosisAndrew Blauvelt, Steven Kempers, Edward Lain, et al.
Journal of the American Academy of Dermatology|July 25, 2022
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosisJoyce M C Teng, Christopher G Bunick, Scott Guenthner, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposureHolm Schneider, Christopher G Bunick, Kathrin Hillmann, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Journal of Drugs in Dermatology : JDD|August 4, 2010
Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimenDavid Pariser, Alicia Bucko, Richard Fried, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Science Advances|May 1, 2024
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, et al.
Pageof 4